Review Article

The Effect of TNF-α on CHD and the Relationship between TNF-α Antagonist and CHD in Rheumatoid Arthritis: A Systematic Review

Yezhou Qian,1 Menghui Mao,1 and Feige Nian2

1Department of Cardiology, The First Hospital of Jiaxing, The Affiliated Hospital of Jiaxing University, Jiaxing, China
2Department of Rheumatology, The First Hospital of Jiaxing, The Affiliated Hospital of Jiaxing University, Jiaxing, China

Correspondence should be addressed to Feige Nian; nfg0220@163.com

Received 28 May 2022; Revised 27 July 2022; Accepted 29 July 2022; Published 24 August 2022

Copyright © 2022 Yezhou Qian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Tumor necrosis factor-alpha (TNF-α) plays an important role in coronary heart disease (CHD), a chronic inflammatory process. Meanwhile, this pro-inflammatory factor is also involved in the pathogenesis of autoimmune diseases such as rheumatoid arthritis (RA). Patients with RA correspond to a higher risk of CHD. TNF-α antagonist, one of the main treatments for RA, may reduce the risk of CHD in patients with RA. This review summarizes the pathogenesis of TNF-α in CHD and discusses the relationship between TNF-α antagonist and CHD in patients with RA.

1. Introduction

In recent years, the incidence of coronary heart disease (CHD) has increased year by year, and its mortality rate has already surpassed that of cancer [1]. The underlying mechanism of CHD is atherosclerosis, and the oxidative modification of low-density lipoprotein cholesterol (LDL-C) is the main cause of plaque formation [2]. At present, the occurrence and development of CHD are generally considered as a chronic inflammatory process and tumor necrosis factor-alpha (TNF-α) has significant effects on the development of CHD [3]. It has been shown that TNF-α is capable of damaging endothelium function, enhancing the uptake of ox-LDL by macrophages, promoting angiogenesis, and triggering the clinical coronary events [4–7]. As a pro-inflammatory cytokine, TNF-α is central to the inflammatory process of autoimmune diseases such as rheumatoid arthritis (RA) [8]. Patients with RA have higher risk of CHD [9]. Meanwhile, TNF-α antagonists have been shown to be effective in controlling inflammatory activity and functional impairment in RA [10]. There is accumulating evidence indicating that the use of TNF-α antagonists is associated with a reduced risk of cardiovascular events in patients with RA [11–19]. However, other studies have found TNF-α antagonists to be associated with no change or increased cardiovascular risk [20, 21]. In this review, we summarize the recent advances of TNF-α in the pathogenesis of CHD and discuss the impact of TNF-α antagonists on CHD in patients with RA.

2. Overview of TNF-α

TNF-α is originally discovered during 1975 that could kill mouse tumor cells, which is why we call it “tumor necrosis factor” [22]. It belongs to the TNF superfamily of proteins consisting of 157 amino acids and is mainly generated by activated macrophages, T-lymphocytes, and natural killer cells [23, 24], but several subsequent studies have shown that it is also produced by nonimmune cells such as endothelial cells, adipocytes, neurons, and myocardial cell [25–28]. TNF-α exists in two forms: transmembrane (tmTNF-α) or soluble TNF-α (sTNF-α) [29]. tmTNF-α is expressed on the surface of activated lymphocytes, macrophages, and other cell types, and when processed by TNF-α-converting enzyme, it is released as the sTNF-α [30, 31]. The biological activity of TNF-α is achieved through two receptors: TNF-α
3.1. **TNF-α and Endothelial Cell.** In vascular homeostasis, vascular endothelial cells act as a barrier [45]. Disruption of the barrier leads to inflammatory cell invasion, which contributes to a variety of vascular diseases, including atherosclerosis [46]. Research suggests that TNF-α disrupts the intercellular connections of endothelial cells and enhances vascular permeability [4, 47]. A large number of studies reveal that endothelial inflammation plays an important role in the progression of atherosclerosis [48]. TNF-α activates endothelial cells and induces monocytes/macrophages to express cytokines and chemokines, which may lead to the progression of atherosclerosis [48]. In the development of atherosclerosis, endothelial cell apoptosis plays an important role in the regulation [4]. TNF-α induces endothelial cell apoptosis by upregulating autophagy, which is inhibited by arachidonic acid [49]. In addition to apoptosis, endothelial cell senescence is positively associated with the development of atherosclerosis [50], and exposure to TNF-α promotes premature endothelial senescence [51].

3.2. **TNF-α and Foam Cell.** In the early stages of atherosclerosis, monocytes migrate to the intima of coronary artery and differentiate into macrophages [52]. When oxidized low-density lipoprotein (ox-LDL) intake exceeds the metabolic capacity of macrophages, macrophages transform into foam cells [43]. Foam cells are involved in fatty streak formation, a hallmark of the early stages of atherosclerosis [53]. The study confirms that TNF-α promotes monocyte adhesion to endothelial cells, which is effectively blocked by adalimumab [54]. Ox-LDL induces oxidative stress and increases TNF-α secretion by macrophages via reducing the inhibition effect of miR-491-5p on matrix metalloproteinase 9 [55]. Meanwhile, TNF-α enhances the uptake of ox-LDL by macrophages in a concentration-dependent manner [5]. There is a vicious circle here, where TNF-α promotes the uptake of ox-LDL by macrophages, and this in turn increases the release of TNF-α. In addition, the formation of foam cells is also associated with impaired cholesterol efflux from macrophages [56]. TNF-α has been shown to reduce cholesterol efflux by suppressing the expression of adenosine triphosphate (ATP)-binding membrane cassette transporter A1 (ABCA1) and liver X receptor-α, and infliximab exerts atheroprotective effect by eliminating the reduction in foam cells induced by TNF-α [57].

3.3. **TNF-α and Angiogenesis.** Angiogenesis is an essential process in a variety of physiological and pathological conditions, including atherosclerosis and rheumatoid arthritis [58]. It contains the differentiation, proliferation, migration, and maturation of endothelial cells [59]. Vascular endothelial growth factor (VEGF) is an important mediator of angiogenesis [60], and VEGF augments vascular endothelial cell proliferation, migration, and survival [60]. TNF-α promotes VEGF expression and angiogenesis [6]. Besides, TNF-α mediates the expression of chemerin in human coronary endothelial cells under hypoxia and promotes the early process of angiogenesis [61]. Studies have shown that chemerin stimulates angiogenesis both in vitro and in vivo to a similar extent as that of VEGF [62]. Chen et al. also found that the angiogenic function of TNF-α is significantly enhanced with the overexpression of angiopeptins 1 and 2 [63]. In endothelial cell inflammatory responses, angiopeptin sensitizes endothelial cells to TNF-α [64].

3.4. **TNF-α and Vascular Smooth Muscle Cell.** Abnormal migration, extracellular matrix synthesis, and proliferation of vascular smooth muscle cells (VSMCs) contribute to the formation of atherosclerotic plaque [65]. TNF-α causes VSMC proliferation and migration through multiple pathways [66–71]. It contains upregulated expression of lncRNA HIX003209, miR-21, lncRNA CAMK2D-associated transcript-1, miR-375-3p, Raf-1/MAPK-dependent manner, and the help of matrix metalloproteinase 2. Vascular calcification is associated with CHD [72]. Adiponectin, secreted by adipocytes, protects VSMCs from calcification induced by beta-glycerophosphate by inhibiting the JAK kinase 2/signal transduction and activator transcription 3 signaling pathway and downregulating the expression of the transcription factor osterix [73]. TNF-α impairs adiponectin multimerization, consequently decreasing adiponectin secretion by altered disulfide bond modification in endoplasmic reticulum [74]. Inflammation is implicated in atherosclerosis along with the accumulation of leukocytes and inflammatory mediators such as interleukin (IL)-1β and IL-6, and TNF-α increases the levels of inflammatory factors in VSMCs [75]. Abnormal oxidative stress in VSMCs plays an important role in the occurrence and development of vascular remodeling and promotes the development of atherosclerosis [76]. This oxidative stress in VSMCs is induced by TNF-α, and overexpression of 17β-estradiol abolishes this pathological process [77]. Atherosclerosis, an age-related cardiovascular disease, is associated with cellular senescence and senescence-associated secretory phenotype in VSMCs [78]. TNF-α is one of the main inflammatory signaling molecules involved in the senescence of VSMCs by inducing the activity of senescence-associated β-galactosidase (SA-β-gal) and telomerase [79]. The specific mechanism of TNF-α in CHD is shown in Figure 1.

3.5. **TNF-α and Myocardial Infarction.** After myocardial infarction, a large amount of TNF-α is produced by ischemia and hypoxia-activated cardiomyocytes and local mononuclear macrophages [80, 81]. At the same time, the
concentrations of TNFR1 and TNFR2 are also significantly increased [82]. STEMI patients with significantly elevated levels of TNF-α are more likely to have subsequent ischemic events, HF, and all cardiovascular events [7]. Since TNF-α induces the release of soluble TNF-α receptors 1 and 2 (sTNFR1 and sTNFR2) into the circulation in STEMI patients, these patients with high circulating sTNFR1 or sTNFR2 are at high risk of adverse clinical events [83]. Furthermore, TNF-α is also involved in adverse remodeling after myocardial infarction [84].

4. **TNF-α Antagonist and CHD in Patients with RA**

4.1. **TNF-α Antagonist in RA.** TNF-α antagonists are developed following the discovery that TNF-α plays a role in the pathophysiology of RA [85]. Five different drugs based on blocking TNF-α are available: infliximab, adalimumab, etanercept, golimumab, and certolizumab pegol [86]. Over the past few decades, numerous clinical trials have been conducted on these compounds, which have shown excellent and comparable efficacy in improving clinical, functional, and radiological disease outcomes in patients with RA [87]. As the most frequently used biologics in RA [88], in addition to some rare but serious systemic side effects, TNF-α antagonists may also exert pharmacological effects beyond the treatment of RA [14, 89, 90].

4.2. **RA and CHD.** Compared with the general population, patients with RA have 1.5–2 times increased risk of myocardial infarction and CHD [9,91]. The study has shown that the risk of cardiovascular disease (CVD) may increase before RA is diagnosed [92]. Patients with RA are often accompanied by disability, but CVD is the leading cause of death [93]. Studies show that the risk of CVD associated with RA is similar to diabetes [94]. Notably, the atherosclerotic burden in RA correlates with the disease severity at baseline [95] and RA activity over time may contribute to the risk of CVD [96]. Systemic inflammation is an important contributor to increased cardiovascular risk in patients with RA [20, 97]. TNF-α plays an important role in this pathological process [98]. Patients with RA are systemically predisposed to high levels of TNF-α [99]. It is generally accepted that RA and atherosclerosis are autoinflammatory diseases involving multiple inflammatory cytokines, with many common genetic predispositions and environmental factors [100].

4.3. **TNF-α Antagonist and Endothelial Cell.** Impaired endothelial cell function has been demonstrated in patients with RA and may contribute to the progression of atherosclerosis in these patients [101, 102]. As a cornerstone of RA treatment, a study shows that TNF-α antagonists improve endothelial function in patients with RA [103]. As a TNF-α antagonist, adalimumab is one of the leading therapies for RA [104]. It limits the inflammation of vascular by preventing endothelial activation, endothelial monocyte adhesion, and endothelial leakage [54]. Certolizumab pegol, another TNF-α antagonist, has also been shown to attenuate the pro-inflammatory state of endothelial cells [105]. Another study on certolizumab pegol indicates that leukocyte adhesion and angiogenesis induced by TNF-α could be suppressed by certolizumab pegol [106]. Endothelial progenitor cells have the ability to differentiate into endothelial cells in situ and limit the formation of atherosclerotic plaque, and short-term treatment of RA with TNF-α antagonists is associated with an increase in circulating endothelial progenitor cells [107]. Elevated levels of some soluble adhesion molecules, such as vascular cell adhesion molecule-1, are associated with endothelial dysfunction and the development of atherosclerosis [108], and administration with a TNF-α antagonist, certolizumab pegol, also has a positive effect on reducing the expression of some adhesion molecules [109].

4.4. **TNF-α Antagonist and Lipid Profile.** Risk factors for CHD include elevated plasma low-density lipoprotein cholesterol (LDL-C) and decreased high-density lipoprotein cholesterol (HDL-C) [110]. Dyslipidemia, considered as a secondary impact of chronic inflammatory state, has been found in patients with RA [111]. Treatment with TNF-α antagonists induces elevated serum HDL-C levels in patients
with RA [112, 113]. This may be due to the fact that during the inflammatory process, the expression of cytokines such as TNF-α reduces the level of circulating HDL-C and TNF-α antagonists have the ability to control disease activity [114]. Results from other literature studies are conflicting, they have not found that TNF-α antagonists affect the levels of HDL-C in patients with RA [115–117], and this may be attributable to the differences in study populations, study duration, therapeutic drugs, and lack of adjustment for covariables such as age and comorbidities. A study by Hassan et al. follows up for 104 weeks, and the result shows no significant changes in the HDL-C and LDL-C values following the use of TNF-α antagonist [118]. Notably, LDL-C decreases significantly throughout the study in patients treated with statins. Concomitant treatment with TNF-α antagonist and statins may reduce the cardiovascular risk in patients with RA in addition to treating the inflammatory component. TNF-α antagonist not only affects the concentration of HDL-C but also enhances the antioxidant capacity of HDL-C and improves its anti-atherosclerotic ability [119]. This may explain that in patients with RA, the incidence of cardiovascular events decreases without higher HDL-C concentrations when treated with TNF-α antagonists.

4.5. TNF-α Antagonist and CHD Events. In patients with RA, the increased burden of CHD, particularly acute myocardial infarction (AMI), is independent of traditional CVD risk factors, and it is partly attributable to chronic systemic inflammation [120]. The use of TNF-α antagonists in RA reduces the risk of CHD events, such as MI, cardiac death, and unstable angina, and these risks are further reduced with long-term use [14], but another study shows that compared with receiving conventional modified antirheumatic drugs, the AMI rate is not reduced in RA treated with TNF-α antagonists, and reduction in this risk presupposes a response to TNF-α antagonists [17]. This finding supports that suppression of inflammation may reduce cardiovascular risk. Circulating TNFR1 levels are associated with mortality risk in AMI [121]. TNFR2 plays an important role in myocardial survival and homeostasis by suppressing apoptosis and necroptosis [122]. Cardioprotective effects of TNF-α antagonists may be related to the inhibition of TNFR1 [123]. However, inhibition of TNFR2, a cardioprotective receptor, by TNF-α antagonists exceeds that of TNFR1, resulting in increased cardiovascular morbidity [99]. The contrast in the risk of CVD can be explained by the difference in doses administered, causing different degrees of inhibition in TNFR2. Besides, the reduction in the risk of CHD events by TNF-α antagonists may be associated with the inappropriate use of glucocorticoids in control patients [19]. The risk of hypertension, diabetes, weight gain, and metabolic syndrome are increased with the use of glucocorticoids [124–126]. Meanwhile, these complications increase the risk of CHD in patients with RA.

4.6. TNF-α Antagonist and Others. RA is an independent risk factor for the development of CHD [127], and this can be explained by a prothrombotic state with abnormalities in the coagulation, fibrinolytic systems, and platelet reactivity [128]. The study provides evidence that the inhibition of fibrinolysis in patients with RA is reduced by TNF-α antagonist [129]. This helps to reduce the risk of thrombosis systematically. In patients with RA, traditional CVD risk factors such as diabetes, hypertension, and hyperlipidemia do not fully account for the increase in atherosclerosis [130]. Insulin resistance increases in patients with RA and is associated with accelerated coronary atherosclerosis [131], and TNF-α antagonists have been shown to improve insulin sensitivity and reduce insulin resistance in patients with RA [132]. Coronary artery calcification is part of the atherosclerotic process and is proportional to the risk of cardiovascular events [133]. It is worth noting that coronary calcium scores are significantly elevated in RA with inflammatory anemia [134], and TNF-α antagonists improve inflammatory anemia in patients with RA [135].

5. Conclusion and Perspective

In conclusion, patients with RA have a significant increase in CHD morbidity and mortality than patients without RA. Inflammation is the common link between CHD and RA. TNF-α is involved as an important inflammatory cytokine. Growing evidence suggests that there is a protective association between TNF-α antagonists and CHD in RA.

From endothelial cell dysfunction to myocardial infarction, TNF-α is widely involved in the occurrence and development of CHD [46, 136, 137]. As a chronic inflammatory disease, TNF-α-involved vascular inflammation plays an important role in the progression of CHD [138]. In local inflammation, TNF-α is released by inflammatory cells, endothelial cells, and cardiomyocytes [23–28]. It then mediates endothelial dysfunction, foam cell formation, angiogenesis, smooth muscle proliferation, and thrombosis [6, 46, 56, 66].

The incidence of CVD is significantly elevated in patients with RA, and it is the leading cause of death in patients with RA [139]. In addition to improving clinical, functional, and radiological disease outcomes in patients with RA [87], TNF-α antagonists, the most frequently used biologics in RA [88], improve endothelial function [103], lipid metabolism [112, 113], and the risk of CHD events [14]. Finally, as biologics become more prominent in the treatment of RA, future research should focus on determining whether TNF-α antagonists may directly exert cardioprotective effects through some unknown mechanism. Considering the pathogenic role of TNF-α in various stages of CHD, TNF-α antagonists may play a positive role in the treatment of CHD in the future.

Data Availability

This is a review, with no underlying data.

Conflicts of Interest

The authors declare that they have no conflicts of interest.
Authors’ Contributions
FN designed the study and revised the manuscript. MM edited the manuscript. YQ drafted the manuscript. All authors have read and approved the content of the manuscript.

Acknowledgments
This research was funded by the Key Medicine Disciplines Co-Construction Project of Jiaxing Municipal (Grant no. 2019-ss-xxgbx).

References
[1] B. Wang, X. Mo, and Z. Wu, “Systematic review and meta-analysis of the correlation between plasma homocysteine levels and coronary heart disease,” Journal of Thoracic Disease, vol. 14, no. 3, pp. 646–653, 2022.
[2] J. Li, T. Cao, J. Han et al., “Comparison of adipose- and bone marrow-derived stem cells in protecting against Ox-LDL-induced inflammation in M1-macrophage-derived foam cells,” Molecular Medicine Reports, vol. 19, no. 4, pp. 2660–2670, 2019.
[3] J. Yuepeng, X. Zhao, Y. Zhao, and L. J. M. Li, “Gene polymorphism associated with TNF-α (G308A) IL-6 (C174G) and susceptibility to coronary atherosclerotic heart disease: a meta-analysis,” Medicine (Baltimore), vol. 98, no. 2, Article ID e13813, 2019.
[4] H. Duan, Q. Zhan, J. Liu, R. Li, and C. J. P. R. Wu, “Suppression of apoptosis in vascular endothelial cell, the promising way for natural medicines to treat atherosclerosis,” Pharmacological Research, vol. 168, Article ID 105599, 2021.
[5] Z. Ding, S. Lui, X. Wang et al., “PCSK9 regulates expression of scavenger receptors and Ox-LDL uptake in macrophages,” Cardiovascular Research, vol. 114, no. 8, pp. 1145–1153, 2018.
[6] L. An, S. Shen, L. Wang et al., “TNF-α increases angiogenic potential in a co-culture system of dental pulp cells and endothelial cells,” Brazilian Oral Research, vol. 33, no. 9, p. e059, 2019.
[7] M. González, J. A. Ruiz-Ros, M. Pérez-Paredes et al., “Prognostic value of tumor necrosis factor-alpha in patients with ST-segment elevation acute myocardial infarction,” Revista Española de Cardiología, vol. 60, no. 12, pp. 1233–1242, 2007.
[8] A. Julià, M. López-Lasanta, F. Blanco, A. Gómez, and S. J. B. M. D. Marsal, “Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor,” Therapy, vol. 22, no. 1, 2021.
[9] O. Schier, C. Tosevski, R. H. Glazier, S. Hogg-Johnson, and E. M. Badley, “Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis,” Annals of the Rheumatic Diseases, vol. 76, no. 8, pp. 1396–1404, 2017.
[10] L. Klareskog, D. van der Heijde, J. P. de Jager et al., “Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial,” The Lancet, vol. 363, no. 9410, pp. 675–681, 2004.
[11] J. D. Greenberg, J. M. Kremer, J. R. Curtis et al., “Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 4, pp. 576–582, 2011.
[12] L. Ljung, J. F. Simard, L. Jacobsson, S. Rantapää-Dahlqvist, and J. Askling, "Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis," Arthritis & Rheumatism, vol. 64, no. 1, pp. 42–52, 2012.
[13] L. T. H. Jacobsson, C. Turesson, A. Gülfe et al., “Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 32, no. 7, pp. 1213–1218, 2005.
[14] A. Bili, X. Tang, S. Pranesh et al., “Research, tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid,” Arthritis Care & Research, vol. 66, no. 3, pp. 355–363, 2014.
[15] D. H. Solomon, J. R. Curtis, K. G. Saag et al., “Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic,” The American Journal of Medicine, vol. 126, no. 8, pp. 730.e9–730.e17, 2013.
[16] L. Ljung, S. Rantapää-Dahlqvist, L. T. H. Jacobsson, and J. Askling, "Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis," Annals of the Rheumatic Diseases, vol. 75, no. 12, pp. 2087–2094, 2016.
[17] W. G. Dixon, K. D. Watson, M. Lunt, K. L. Hyrich, A. J. Silman, and D. P. M. Symmons, "Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British society for rheumatology biologics register," Arthritis & Rheumatism, vol. 56, no. 9, pp. 2905–2912, 2007.
[18] L. Ljung, J. Askling, and S. R. D. A. Research, "Therapy, the risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population," A National Cohort Study, vol. 16, no. 3, pp. 1–10, 2014.
[19] G. Ozen, S. Pedro, and K. J. T. O. R. Michaud, "The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis," Journal of Rheumatology, vol. 48, no. 5, pp. 648–655, 2020.
[20] D. H. Solomon, J. Avorn, J. N. Katz et al., "Reduction of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis," Arthritis & Rheumatism, vol. 64, no. 1, pp. 3790–3798, 2006.
[21] J. Zhang, F. Xie, and H. Yun, "Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis," Annals of the Rheumatic Diseases, vol. 75, no. 10, pp. 1813–1818, 2016.
[22] D. A. Ca Rswell, L. J. Old, R. L. Kassel, S. Green, N. Fiore, and B. Williamson, "An endotoxin-induced serum factor that causes necrosis of tumors," Proceedings of the National Academy of Sciences, vol. 72, no. 9, pp. 3666–3670, 1975.
[23] B. B. Aggarwal, "Signalling pathways of the TNF superfamily: a double-edged sword," Nature Reviews Immunology, vol. 3, no. 9, pp. 745–756, 2003.
[24] T. J. Horiiuchi, "Transmembrane TNF-α: structure, function and interaction with anti-TNF agents," Rheumatology, vol. 49, no. 7, pp. 1215–1228, 2010.
[25] L. C. Gahrng, N. G. Carlson, R. A. Kulmer, and S. W. J. N. Rogers, "Neuronal expression of tumor necrosis factor alpha in the murine brain," Neuroimmunomodulation, vol. 3, no. 5, pp. 289–303, 1996.
mellitus.” *American Journal of Therapeutics*, vol. 24, no. 3, pp. e347–e350, 2017.

[90] Y. O. Ayyildiz, M. G. Vural, T. H. Efe, A. G. Ertend, and R. J. H. J. o. C. Akdemir, “Effect of long-term TNF-α inhibition with infliximab on left ventricular torsion in patients with rheumatoid,” *Arthritis*, vol. 56, no. 5, pp. 406–413, 2015.

[91] C. Han, D. W. Robinson, M. V. Hackett, L. C. Paramore, K. H. Fraeman, and M. Bala, “Cardiovascular disease and risk factors in patients with rheumatoid arthritis,” *Psoriatic Arthritis, and Ankylosing Spondylitis*, vol. 33, no. 11, pp. 2167–2172, 2006.

[92] E. Nikipherou, S. D. Lusignan, C. D. Mallen, K. Khavandi, and K. J. H. Raza, “Cardiovascular risk factors and outcomes in early rheumatoid arthritis,” *A Population-Based Study*, vol. 106, no. 20, 2020.

[93] P. W. Meyer, R. Anderson, J. A. Ker, and M. Ally, “Rheumatoid arthritis and risk of cardiovascular disease,” *Cardiovascular Journal of Africa*, vol. 29, no. 5, pp. 317–321, 2018.

[94] Y. Kazuki, “Time-varying association of rheumatoid arthritis disease activity to subsequent cardiovascular risk,” *ACR Open Rheumatology*, vol. 4, no. 7, pp. 587–595, 2022.

[95] J. Bjrsenius, S. Rantap-Dahlqvist, E. Berglin, and A. Sdergren, “Extent of atherosclerosis after 11-year prospective follow-up in patients with early rheumatoid arthritis was affected by disease severity at diagnosis,” *Scandinavian Journal of Rheumatology*, vol. 49, no. 6, pp. 443–451, 2020.

[96] E. A. A. Arts, J. Fransen, A. A. den Broeder, C. D. Popa, and P. L. C. M. van Riel, “The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients,” *Annals of the Rheumatic Diseases*, vol. 74, no. 6, pp. 998–1003, 2015.

[97] J. Halacoglu and L. Shea, “Cardiovascular risk assessment and therapeutic implications in rheumatoid arthritis,” *Journal of Cardiovascular Translational Research*, vol. 13, no. 5, pp. 878–890, 2020.

[98] A. V. Sorokin and N. Mehta, “The Relationship between TNF-Alpha Driven Inflammation, Lipids, and Endothelial Function in Rheumatoid Arthritis: A Complex Puzzle Continues,” *Cardiovascular Research*, vol. 118, no. 1, pp. 10–12, 2021.

[99] A. Hussain, T. Tarahomi, L. Singh, M. Bollampally, M. Heydari-Kamjani, and M. M. J. C. Kesselman, “Cardiovascular risk associated with TNF alpha inhibitor use in patients with rheumatoid arthritis,” *Cureus*, vol. 13, no. 9, Article ID e17938, 2021.

[100] M. Zhang, M. Wang, Y. Tai, J. Tao, and Q. Wang, “Triggers of cardiovascular diseases in rheumatoid arthritis,” *Current Problems in Cardiology*, vol. 47, no. 6, Article ID 100853, 2021.

[101] M. N. D. Di Minno, P. Ambrosino, R. Lupoli et al., “Clinical assessment of endothelial function in patients with rheumatoid arthritis: a meta-analysis of literature studies,” *European Journal of Internal Medicine*, vol. 26, no. 10, pp. 835–842, 2015.

[102] E. Ikddahl, J. Hisdal, and S. Rollefstad, “Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study,” *Journal of Arthritis Research & Therapy*, vol. 17, no. 1, pp. 1–7, 2015.

[103] F. Ursini, C. Leporini, F. Bene et al., “Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis,” *Scientific Reports*, vol. 7, no. 1, p. 5346, 2017.

[104] C. Peter, E., C. Taylor, and D. Keystone, “Baricitinib versus placebo or adalimumab in rheumatoid arthritis,” *New England Journal of Medicine*, vol. 376, no. 7, 2017.

[105] S. K. Heathfield, B. Parker, L. Zeef, I. N. Bruce, M. Y. J. C. Alexander, and E. Rheumatology, “Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective,” *Clinical and Experimental Rheumatology*, vol. 31, no. 2, pp. 225–233, 2013.

[106] S. Qiang, M. A. Amin, and J. H. R. J. A. Research, “Suppression of endothelial cell activity by inhibition of TNF,” *Therapy*, vol. 14, no. 2, 2012.

[107] F. R. Spinelli, A. Metere, C. Barbati et al., “Effect of therapeutic inhibition of TNF on circulating endothelial progenitor cells in patients with rheumatoid arthritis,” *Mediators of Inflammation*, vol. 2013, Article ID 357359, 2013.

[108] H. Hai-Feng, Y. Na, G. Qing et al., “Citriviridin enhances atherogenesis in hypercholesterolemic ApoE-deficient mice via upregulating inflammation and endothelial,” *Disfuncion*, vol. 10, no. 5, Article ID e0125956, 2015.

[109] S. K. Heathfield, B. Parker, L. A. H. Zeef, I. N. Bruce, and M. Alexander, “Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective,” *Clinical and Experimental Rheumatology*, vol. 31, no. 2, pp. 225–233, 2013.

[110] H. H. Wang, G. Garruti, L. Min, P. Portincasa, and Q. Wang, “Cholesterol and lipoprotein metabolism and atherosclerosis: recent advances in reverse cholesterol,” *Transport*, vol. 16, p. 21, 2017.

[111] E. Uzma, A. Tasnim, and K. Danish, “Lipid abnormalities in patients with rheumatoid arthritis,” *Pakistan journal of Medical Sciences*, vol. 33, no. 1, p. 227, 2017.

[112] E. Spanakis, P. Sidiroopoulos, J. Papadakis et al., “Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab,” *Journal of Rheumatology*, vol. 33, no. 12, pp. 2440–2446, 2006.

[113] B. Seriolo, S. Paolino, A. Sulli, D. Fasciolo, and M. Cutolo, “Anti-TNF-alpha treatment on lipid profile in rheumatic diseases,” *Arthritis Research & Therapy*, vol. 10, no. 1, p. 5346, 2016.

[114] M. Soubrier, P. Jouanel, S. Mathieu et al., “Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis,” *Annals of the New York Academy of Sciences*, vol. 1069, no. 1, pp. 414–419, 2006.

[115] P. Nicolas, A. Maria, J. A. Lopez-Olivo, and L. J. C. Martinez, “A systematic review of the effect of TNF-α antagonists on lipid profiles in patients with rheumatoid arthritis,” *Clinical Rheumatology*, vol. 29, no. 9, pp. 947–955, 2010.

[116] M. Soubrier, P. Jouanel, S. Mathieu et al., “Effects of anti-TNF-alpha treatment on lipid profile in patients with rheumatoid arthritis,” *Current Problems in Cardiology*, vol. 47, no. 6, Article ID 100853, 2021.
[119] C. Popa, L. J. H. van Tits, P. Barrera et al., “Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients,” *Annals of the Rheumatic Diseases*, vol. 68, no. 6, pp. 868–872, 2009.

[120] J. Chen, L. V. Norling, and D. J. C. Cooper, “Cardiac dysfunction in rheumatoid arthritis: the role of inflammation,” *Cells*, vol. 10, no. 4, p. 881, 2021.

[121] M. Park, D. Maristany, D. Huang, M. G. Shlipak, and M. J. A. Whooley, “Associations of tumor necrosis factor alpha receptor type 1 with kidney function decline, cardiovascular events, and mortality risk in persons with coronary artery disease: data from the Heart and Soul Study,” *Atherosclerosis*, vol. 263, pp. 68–73, 2017.

[122] L. Li, Q. Liu, Y. Chen, and H. Yin, “Cardioprotective role of tumor necrosis factor receptor-associated factor 2 by suppressing apoptosis and necroptosis,” *Circulation*, vol. 136, no. 8, pp. 729–742, 2017.

[123] D. L. Faustman, “TNF receptor 2 and disease: autoimmunity and regenerative medicine,” *Frontiers in Immunology*, vol. 4, p. 478, 2013.

[124] G. Özen, S. Pedro, M. E. Holmqvist, M. Avery, F. Wolfe, and K. Michaud, “Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 76, no. 5, pp. 849–854, 2017.

[125] J. F. Baker, B. C. Sauer, G. W. Cannon et al., “Changes in body mass related to the initiation of disease-modifying therapies in rheumatoid arthritis,” *Arthritis & Rheumatology*, vol. 68, no. 8, pp. 1818–1827, 2016.

[126] J. C. Wilson, K. Sarsour, S. Gale, A. Pethö-Schramm, S. S. Jick, and C. R. Meier, “Incidence and risk of glucocorticoid-associated adverse effects in patients with rheumatoid arthritis,” *Arthritis Care & Research*, vol. 71, no. 4, pp. 498–511, 2019.

[127] E. Rezuş, L. A. Macovei, A. M. Burlui, A. Cardoneanu, and C. L. L. Rezuş, “Ischemic heart disease and rheumatoid arthritis—two conditions, the same background,” *Life*, vol. 11, no. 10, p. 1042, 2021.

[128] S. M. Türk, D. Ü Cansu, H. Ü. Teke et al., “Can we predict thrombotic tendency in rheumatoid arthritis?” *Clinical Rheumatology*, vol. 37, no. 9, pp. 2341–2349, 2018.

[129] F. Ingegnoli, E. Fantini, S. Griffini, A. Soldi, P. L. Meroni, and M. Cugno, “Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis,” *Clinical & Experimental Rheumatology*, vol. 28, no. 2, pp. 254–257, 2010.

[130] J. T. Giles, S. Danielides, M. Szko et al., “Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis,” *Arthritis & Rheumatology*, vol. 67, no. 3, pp. 626–636, 2015.

[131] A. Guin, P. Sinhamahapatra, S. Misra, S. R. Choudhury Mazumder, S. Chatterjee, and A. J. b. j. Ghosh, “Incidence and effect of insulin resistance on progression of atherosclerosis in rheumatoid arthritis patients of long disease duration,” *Biomedical Journal*, vol. 42, no. 6, pp. 394–402, 2019.

[132] A. N. Burska, R. Sakthiswary, and N. J. P. O. Sattar, “Effects of tumour necrosis factor antagonists on insulin sensitivity/resistance in rheumatoid arthritis: a systematic review and meta-analysis,” *A Systematic Review and Meta-Analysis*, vol. 10, no. 6, Article ID e0128889, 2015.